Key facts
- Ixcela’s last known valuation is $14.2M (Oct 2020).
- It has raised $8.1M across 2 recorded rounds; the latest was Seed Round ($3.8M) in Oct 2020.
- Notable investors include iD Ventures America.
- Ixcela has filed 3 Form Ds with the SEC since 2017, most recently Oct 2020 ($3.8M sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ixcela
Funding rounds
2 roundsAbout Ixcela
Operator of a biotech company intended to improve internal fitness. The company identifies key small molecules associated with gut microbiome imbalances and develops individualized therapy to restore these molecules to their proper levels with a personalized program that includes proprietary supplements, as well as personalized nutrition and fitness plans, enabling individuals to address common health issues such as irritable bowel syndrome, acid reflux, and leaky gut.
- Sector
- Healthcare
- HQ
- Beverly, MA, United States
- Founded
- 2012
- Employees
- 12
- Website
- ixcela.com/
- Ownership
- Privately Held (backing)
Ixcela doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ixcela shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ixcela in its N-PORT filings yet. We sweep new filings monthly.